| Literature DB >> 30572626 |
Yahua Cui1, Yujia Mo2, Qi Zhang3, Wanwan Tian4, Yutao Xue5, Jie Bai6, Shouying Du7.
Abstract
Paeoniflorin, the main component of total glucosides of paeony (TGP), shows good therapeutic effects in arthritis, but has low bioavailability when administered orally. Avoiding such a deficiency for topical administration would expand its clinical application. This study aimed to avoid these limitations by using nanotechnology (ethosomes) and a physical approach (microneedles). Paeoniflorin-loaded ethosomal formulation (TGP-E) was optimized and evaluated in terms of entrapment efficiency (EE), particle size (PS), zeta potential (ZP), polydispersity index (PDI) and morphology. TGP-E was prepared by the hot injection method and optimized by single-factor tests and an orthogonal experimental design. The optimized paeoniflorin-loaded ethosomes had EE of 27.82 ± 1.56%, PS of 137.9 ± 7.57 nm with PDI of 0.120 ± 0.005, ZP of -0.74 ± 0.43 mV. Ethosomes showed a nearly spherical shape under the transmission electron microscope (TEM). The optimal microneedle-assisted (MN-assisted) conditions were obtained at a microneedle length of 500 μm, a pressure of 3 N and an action time of 3 min. The cumulative penetration amounts (Qn) of TGP solution transdermal (ST) and MN-assisted TGP solution transdermal (MST) were 24.42 ± 8.35 μg/cm² and 548.11 ± 10.49 μg/cm², respectively. Qn of TGP-E transdermal (PT) and MN-assisted TGP-E transdermal (MPT) were 54.97 ± 4.72 μg/cm² and 307.17 ± 26.36 μg/cm², respectively. These findings indicate that use of ethosomes and microneedles can both enhance the penetration ofpaeoniflorin, but for the water-soluble drug, there is no obvious synergism between nanotechnology and microneedles for enhancing penetration in a transdermal drug delivery system.Entities:
Keywords: Paeoniflorin; ethosomes; microneedle; total glucosides of paeony; transdermal
Mesh:
Substances:
Year: 2018 PMID: 30572626 PMCID: PMC6321034 DOI: 10.3390/molecules23123371
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Effects mass ratio of PC, and mass ratio of TGP and PC on EE. (a) mass ratio of PC; (b) mass ratio of TGP and PC (n = 3).
Independent variables and the corresponding levels in the orthogonal experiment design.
| Variables | Levels | ||
|---|---|---|---|
| 1 | 2 | 3 | |
| A/% | 2 | 4 | 5 |
| B | 1:10 | 1:20 | 1:40 |
| C | 5 | 6.5 | 7.3 |
Experimental design and measured responses.
| No. | Variables | Response | |||||
|---|---|---|---|---|---|---|---|
| A (mmol) | B (mg) | C | Errors | EE (%) | DL (%) | ||
| 1 | 1 (0.26) | 1 (20) | 1 (5) | 1 | 8.44 | 0.17 | |
| 2 | 1 (0.26) | 2 (10) | 2 (6.5) | 2 | 8.25 | 0.08 | |
| 3 | 1 (0.26) | 3 (5) | 3 (7.3) | 3 | 15.18 | 0.08 | |
| 4 | 2 (0.52) | 1 (40) | 2 (6.5) | 3 | 12.08 | 0.49 | |
| 5 | 2 (0.52) | 2 (20) | 3 (7.3) | 1 | 19.58 | 0.40 | |
| 6 | 2 (0.52) | 3 (10) | 1 (5) | 2 | 15.95 | 0.16 | |
| 7 | 3 (0.65) | 1 (50) | 3 (7.3) | 2 | 27.85 | 1.39 | |
| 8 | 3 (0.65) | 2 (25) | 1 (5) | 3 | 21.49 | 0.54 | |
| 9 | 3 (0.65) | 3 (12.5) | 2 (6.5) | 1 | 18.06 | 0.23 | |
| EE (%) | K1 | 31.86 | 48.36 | 45.87 | 46.08 | ||
| K2 | 47.61 | 49.31 | 38.39 | 52.04 | |||
| K3 | 67.39 | 49.19 | 62.60 | 48.74 | |||
| REE | 35.53 | 0.95 | 24.22 | 5.96 | |||
| DL (%) | K1 | 0.33 | 2.05 | 0.86 | 0.79 | ||
| K2 | 1.04 | 1.02 | 0.80 | 1.63 | |||
| K3 | 2.16 | 0.46 | 1.87 | 1.10 | |||
| RDL | 1.83 | 1.59 | 1.07 | 0.31 | |||
Analysis in variance of the orthogonal experiment.
| Response | Sources of Variation | Sum of Squares | df | Mean Square | F Value | Significance | |
|---|---|---|---|---|---|---|---|
| EE | A | 13.17 | 2 | 6.59 | 28.04 | 0.0001 | *** |
| B | 19.16 | 2 | 9.58 | 40.78 | <0.0001 | *** | |
| C | 496.29 | 2 | 248.14 | 1056.26 | <0.0001 | *** | |
| Error | 6.08 | 2 | 3.04 | ||||
| DL | A | 1.13 | 2 | 0.56 | 50994.0 | <0.0001 | *** |
| B | 0.86 | 2 | 0.43 | 38908.5 | <0.0001 | *** | |
| C | 0.48 | 2 | 0.24 | 21799.5 | <0.0001 | *** | |
| Error | 0.24 | 2 | 0.12 |
*** P < 0.001.
Selection and verification of optimized parameters.
| Batches | EE (%) | DL (mg/mL) | ||||
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 1 | 2 | 3 | |
| A3B1C3 | 29.27 | 25.99 | 28.2 | 1.46 | 1.30 | 1.41 |
| A3B2C3 | 31.17 | 28.54 | 31.88 | 0.78 | 0.72 | 0.81 |
| A3B3C3 | 33.98 | 30.09 | 27.79 | 0.43 | 0.38 | 0.35 |
| >0.05 | <0.05 | |||||
| Mean score | 1 > 2 > 3 | |||||
| Optimal conditions | A3B1C3 | |||||
Characterization of TGP-E (mean ± SD, n = 3).
| Day | EE (%) | PS (nm) | ZP (mV) | PDI |
|---|---|---|---|---|
| 0 | 27.82 ± 1.56 | 137.9 ± 7.57 | −0.74 ± 0.43 | 0.120 ± 0.005 |
| 10 | 26.07 ± 1.07 | 145.3 ± 2.69 | −0.64 ± 0.42 | 0.122 ± 0.002 |
| 40 | 23.29 ± 1.39 | 206.8 ± 13.36 | −0.91 ± 1.58 | 0.254 ± 0.010 |
Figure 2Particle size distribution (A) initial vesicle; (B) in 10 days; (C) in 40 days (n = 3).
Figure 3Morphology of vesicles under TEM.
Kinetics equations of Pae ex vivo skin permeation exposed to different MN conditions.
| Group | Steady-state Absorption Curve Regression Equation | r | Kp × 10−3 cm−2·h−1 | ER | ||
|---|---|---|---|---|---|---|
| Control | 0.9973 | 2.57 | 0.91 ± 0.18 | |||
| G1 | 250 μm-2 min-3 N | 0.9997 | 10.45 | 3.31 ± 0.48 | 3.64 | |
| G2 | 500 μm-2 min-3 N | 0.9999 | 26.02 | 7.80 ± 0.73 | 8.57 | |
| G3 | 750 μm-2 min-3 N | 0.9992 | 37.56 | 10.02 ± 0.76 | 11.01 | |
| G4 | 1000 μm-2 min-3 N | 0.9998 | 55.84 | 16.26 ± 1.06 | 17.87 | |
| G5 | 500 μm-2 min-1 N | 0.9969 | 10.67 | 3.52 ± 0.18 | 3.87 | |
| G6 | 500 μm-2 min-5 N | 0.9931 | 31.89 | 10.01 ± 0.99 | 11.00 | |
| G7 | 500 μm-2 min-7 N | 0.9989 | 77.49 | 21.70 ± 1.64 | 23.85 | |
| G8 | 500 μm-1 min-3 N | 0.9997 | 23.71 | 7.16 ± 0.57 | 7.87 | |
| G9 | 500 μm-3 min-3 N | 0.9998 | 50.29 | 13.69 ± 0.53 | 15.04 | |
| G10 | 500 μm-5 min-3 N | 0.9993 | 66.03 | 17.17 ± 2.72 | 18.87 | |
Figure 4Cumulative ex vivo skin permeation for the TGP solution under different microneedle conditions (G1 through G10) (n = 3).
Figure 5Skin state 2 h after microneedle application (G3) MN condition of group 3, 750 μm-2 min-3 N; (G4) MN condition of group 4, 1000 μm-2 min-3 N; (G6) MN condition of group 6, 500 μm-2 min-5 N; (G7) MN condition of group 7, 500 μm-2 min-7 N; (G9) MN condition of group 9, 500 μm-3 min-3 N; (G10) MN condition of group 10, 500 μm-5 min-3 N.
Figure 6Cumulative ex vivo skin permeation (a) TGP-S and MN-assisted TGP-S; (b) TGP-E and MN-assisted TGP-E; (c) TGP-S and TGP-E; (d) TGP-E, MN-assisted TGP-S and MN-assisted TGP-E (n = 3).
Figure 7Size distribution of receiver samples (A) Samples of TGP-E in ex vivo skin permeation at 4 h; (B) Samples of MN-assisted TGP-E in ex vivo skin permeation at 4 h.